Funding for this research was provided by:
Zoetis (doanted oclacitinib tablets)
CAPES (Finance code 001)
Text and Data Mining valid from 2019-05-08
Received: 12 December 2018
Accepted: 29 April 2019
First Online: 8 May 2019
: This study was submitted and approved by the Veterinary Institute Ethics Committee (CEUA/IV) (number 4534191017).
: Not applicable.
: The oclacitinib tablets were donated by Zoetis.Alexandre Merlo is a current employee of Zoetis in Brazil.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.